Mircea Basaraba, MD
Cardiovascular Disease · Winchester, TNNPI 1316974637
Payments from drug & device makers
Across 310 payments — averaging $252.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$68K
- Penumbra, Inc.$1K
- Medtronic$1K
- Cardiovascular Systems Inc.$1K
- Boston Scientific$959
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$926
- plus $4K from 31 others
What the payments were for
- Travel & lodging$3,2374%
- Food & beverage$6,8119%
- Education$7,1229%
- Other$61,11778%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 14 | $68,302 |
| Penumbra, Inc. | 3 | $1,330 |
| Medtronic(2 entities) | 22 | $1,261 |
| Cardiovascular Systems Inc. | 12 | $1,228 |
| Boston Scientific | 8 | $959 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 59 | $926 |
| Novartis | 53 | $841 |
| Johnson & Johnson | 29 | $668 |
| Bard Peripheral Vascular, Inc. | 11 | $553 |
| Sanofi-aventis U.S. LLC | 18 | $282 |
| Merck | 14 | $267 |
| Abiomed | 3 | $199 |
| Boehringer Ingelheim | 8 | $152 |
| AstraZeneca | 8 | $139 |
| Abbott | 5 | $123 |
| Inari Medical, Inc. | 1 | $117 |
| Philips North America LLC | 1 | $108 |
| Pfizer | 5 | $104 |
| Edwards Lifesciences | 1 | $88 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Sanofi | 2 | $63 |
| Amgen | 4 | $62 |
| Novo Nordisk | 3 | $57 |
| Bayer | 2 | $46 |
| Shockwave Medical, Inc | 1 | $46 |
| Baxter Healthcare | 2 | $38 |
| Venclose Inc. | 2 | $35 |
| Reflow Medical Inc | 2 | $28 |
| Bardy Diagnostics, Inc. | 4 | $28 |
| Impulse Dynamics (USA) Inc. | 2 | $28 |
| Qorumpartners | 1 | $24 |
| Coala Life Inc | 1 | $23 |
| Stryker | 1 | $19 |
| Recor Medical Inc | 1 | $18 |
| Biocompatibles, Inc. | 1 | $18 |
| Cordis US CORP. | 1 | $18 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$49,917
- VenaCure 1470 Pro$13,600
- EVLT$4,293
- Indigo System$1,330
- GENERAL - THERAPIES$763
- Diamondback Peripheral$743
- Micra$738
- FLOWTRIEVER CATHETER, S$233
- Venclose Maven Catheter$233
- Rotarex$140
- (4066) Tack Endo Sys ATK$108
How this compares
$78,287 in reported general payments places this provider in the 85th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 382 | $363,368 |
| EntrestoSacubitril/Valsartan | 301 | $329,372 |
| EliquisApixaban | 227 | $232,610 |
| FarxigaDapagliflozin Propanediol | 148 | $114,393 |
| JardianceEmpagliflozin | 62 | $66,539 |
| Repatha SyringeEvolocumab | 46 | $31,639 |
| Repatha SureclickEvolocumab | 49 | $29,193 |
| VerquvoVericiguat | 29 | $20,904 |
| MultaqDronedarone Hcl | 13 | $11,380 |
| Losartan Potassium | 632 | $7,228 |
| Nebivolol Hcl | 65 | $4,823 |
| Lisinopril | 522 | $4,435 |
| Atorvastatin Calcium | 320 | $4,415 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 113 | $4,364 |
| DapagliflozinDapagliflozin Propanediol | 11 | $4,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $668 | $363,368382 claims |
| NovartisEntresto | $841 | $329,372301 claims |
| PfizerEliquis | $104 | $232,610227 claims |
| AstraZenecaFarxiga | $139 | $114,393148 claims |
| Boehringer IngelheimJardiance | $152 | $66,53962 claims |
| MerckVerquvo | $267 | $20,90429 claims |
| Sanofi-aventis U.S. LLCMultaq | $282 | $11,38013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Winchester
- Brian LindmanNashville$5.5M
- David MetzgerKingsport$4.8M
- Christopher EllisNashville$4.1M
- Dinesh GuptaNashville$3.2M
- Joann LindenfeldNashville$2.2M
- Frank McGrewMemphis$2.1M
- Rebecca HungNashville$1.8M
- Mohsin AlhaddadJackson$1.8M
- Robert SmithBrentwood$1.3M
- Travis RichardsonNashville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.